ACADIA Pharmaceuticals (MEX:ACAD) EPS without NRI: MXN39.89 (TTM As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN362.00
GF Value MXN350.43
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals EPS without NRI?

ACADIA Pharmaceuticals MEX:ACAD 73 EPS without NRI is MXN39.89 as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN350.43 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,170 Biotechnology companies, ACADIA Pharmaceuticals ranks worse than 85470% on this metric.

ACADIA Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2026 was MXN0.36. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was MXN39.89.

During the past 12 months, ACADIA Pharmaceuticals's average earnings per share (NRI) Growth Rate was 60.60% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for ACADIA Pharmaceuticals's EPS without NRI or its related term are showing as below:

During the past 13 years, ACADIA Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 40.90% per year. The lowest was -74.60% per year. And the median was 8.80% per year.

MEX:ACAD's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.75
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

ACADIA Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was MXN0.36. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN39.89.

ACADIA Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was MXN0.36. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN40.43.


ACADIA Pharmaceuticals  (MEX:ACAD) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ACADIA Pharmaceuticals EPS without NRI Related Terms


ACADIA Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals EPS without NRI Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.54 -26.13 -6.28 12.25 41.41

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 3.01 7.71 28.81 0.36

MEX:ACAD vs VKTX, EWTX, DNLI: EPS without NRI Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's PE Ratio without NRI falls into.


MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN39.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of MXN39.89 mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a EPS without NRI of MXN39.89 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ACADIA Pharmaceuticals and its competitors. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 1170 companies in the Biotechnology industry.
Is ACADIA Pharmaceuticals' EPS without NRI too high?
ACADIA Pharmaceuticals' current EPS without NRI is MXN39.89. Based on the distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 1170 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' EPS without NRI compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #999999 out of 1170 companies for EPS without NRI. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current EPS without NRI is MXN39.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN350.43, compared to a current price of MXN362.00 — trading 3.3% above its estimated fair value. The current EPS without NRI is MXN39.89. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current EPS without NRI is MXN39.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN362.00 is trading 3.3% above its estimated GF Value™ of MXN350.43. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • EPS without NRI: MXN39.89
  • GF Value™: MXN350.43 vs. price of MXN362.00 (3.3% above fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN362.00
Price
MXN350.43
GF Value